BI 764532: DLL3/CD3 T-cell engager
BI 764532: DLL3/CD3 T-cell engager
Search
Groundbreaking oncology research zongertinib
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
BI 764532: DLL3/CD3 T-cell engager | ep-NEC
BI 764532: DLL3/CD3 T-cell engager | ep-NEC
Our Biotech Story | Bioxcellence | Boehringer Ingelheim
Discover our pioneering history & leadership in biotechnology, driving innovation in biopharmaceutical manufacturing & breakthrough therapies.
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
Boehringer Ingelheim collaborates with Circle Pharma
Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Partnership to Develop Urea Cycle Disorders Therapy
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Targeting HER2 in cancer: The story of zongertinib
We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
Second cancer immunotherapy partnership with 3T Bio
Second cancer immunotherapy partnership with 3T Bio
Upstream and Downstream Processing | Bioxcellence | Boehringer Ingelheim
Experience our exceptional expertise in upstream & downstream biopharmaceutical processing, utilizing mammalian cell cultures & microbial organisms.
Ileitis prevention vaccination Lawsonia intracellularis pig
Cause, impact and prevention: Learn the essentials about Ileitis
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
emperor-preserved-heart-failure-full-data
Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Boehringer Olaf Scholz break ground for innovation center
Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center
Annelises story
Listen to Annelise discuss her journey after diagnosis with systemic sclerosis, also known as scleroderma
Monoclonal Antibody Production | Bioxcellence | Boehringer Ingelheim
Explore our advanced capabilities in antibody production, and learn about the unique features of monoclonal & polyclonal antibodies.
Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
Zongertinib positive results non-small cell lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Collaboration-with-OxfordBioTherapeutics
Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Stargardt Disease
Stargardt Disease is a hereditary condition which causes degeneration of cells in the retina at the back of the eye.
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.
Four Pillars Cancer Immunology
Boehringer Ingelheim is focusing cancer immunology research on T cell engagers, cancer vaccines, oncolytic viruses and immune & stromal modulation